Cargando…

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin

Detalles Bibliográficos
Autores principales:	Zauli, Giorgio, Rimondi, Erika, Secchiero, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2008
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401137/ https://www.ncbi.nlm.nih.gov/pubmed/18266968 http://dx.doi.org/10.1111/j.1582-4934.2008.00265.x

Ejemplares similares

TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?
por: Bernardi, Stella, et al.
Publicado: (2019)

Circulating TRAIL Shows a Significant Post-Partum Decline Associated to Stressful Conditions
por: Zauli, Giorgio, et al.
Publicado: (2011)

Association of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Central Adiposity and Low-Density Lipoprotein Cholesterol
por: Brombo, Gloria, et al.
Publicado: (2013)

GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients
por: Tisato, Veronica, et al.
Publicado: (2013)

Clinical perspectives of TRAIL: insights into central nervous system disorders
por: Tisato, Veronica, et al.
Publicado: (2016)

TRAIL Modulates the Immune System and Protects against the Development of Diabetes
por: Bossi, Fleur, et al.
Publicado: (2015)

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017)

Inhibitory Effect of Natural Anti-Inflammatory Compounds on Cytokines Released by Chronic Venous Disease Patient-Derived Endothelial Cells
por: Tisato, Veronica, et al.
Publicado: (2013)

Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease
por: Arcidiacono, Maria Vittoria, et al.
Publicado: (2018)

Palmitic Acid Induced a Long-Lasting Lipotoxic Insult in Human Retinal Pigment Epithelial Cells, which Is Partially Counteracted by TRAIL
por: Sergi, Domenico, et al.
Publicado: (2022)

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3
por: Agnoletto, Chiara, et al.
Publicado: (2014)

Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1
por: Voltan, Rebecca, et al.
Publicado: (2016)

Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity
por: Marcuzzi, Annalisa, et al.
Publicado: (2021)

Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction
por: Secchiero, Paola, et al.
Publicado: (2009)

TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake
por: Toffoli, Barbara, et al.
Publicado: (2021)

The anti-leukemic activity of sodium dichloroacetate in p53(mutated/null) cells is mediated by a p53-independent ILF3/p21 pathway
por: Agnoletto, Chiara, et al.
Publicado: (2014)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
por: Burgess, Teresa L., et al.
Publicado: (1999)

Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women
por: Tisato, Veronica, et al.
Publicado: (2017)

Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus
por: Tornese, Gianluca, et al.
Publicado: (2015)

Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy
por: Tisato, Veronica, et al.
Publicado: (2015)

Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation
por: Rewiuk, Krzysztof, et al.
Publicado: (2015)

The Mechanism of Osteoprotegerin-Induced Osteoclast Pyroptosis In Vitro
por: Zhu, Jiaqiao, et al.
Publicado: (2023)

Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity
por: Li, Binghan, et al.
Publicado: (2016)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

The Function of Naringin in Inducing Secretion of Osteoprotegerin and Inhibiting Formation of Osteoclasts
por: Xu, Tong, et al.
Publicado: (2016)

Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model
por: Tisato, Veronica, et al.
Publicado: (2014)

Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand Pathway
por: Liu, Wei, et al.
Publicado: (2015)

Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
por: Zauli, Giorgio, et al.
Publicado: (2020)

SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient
por: Rizzo, Roberta, et al.
Publicado: (2021)

TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress
por: Tisato, Veronica, et al.
Publicado: (2018)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
por: Lane, Denis, et al.
Publicado: (2012)

Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone
por: Wang, Baoli, et al.
Publicado: (2015)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
por: Rimondi, Erika, et al.
Publicado: (2021)

Osteoclast Fusion and Fission
por: Jansen, Ineke D. C., et al.
Publicado: (2012)

Osteoprotegerin reduces osteoclast resorption activity without affecting osteogenesis on nanoparticulate mineralized collagen scaffolds
por: Ren, Xiaoyan, et al.
Publicado: (2019)

Inhibitory effects of osteoprotegerin on osteoclast formation and function under serum-free conditions
por: Fu, Ying-Xiao, et al.
Publicado: (2013)

Involvement of the Ca(2+) signaling pathway in osteoprotegerin inhibition of osteoclast differentiation and maturation
por: Fu, Yingxiao, et al.
Publicado: (2015)

Lipids at the Nexus between Cerebrovascular Disease and Vascular Dementia: The Impact of HDL-Cholesterol and Ceramides
por: Sergi, Domenico, et al.
Publicado: (2023)

Suppression of AMP‐activated protein kinase reverses osteoprotegerin‐induced inhibition of osteoclast differentiation by reducing autophagy
por: Tong, Xishuai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_um5sjt0nq0042a7ffqpvs1hdbg